Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors should avoid the sector altogether. Many healthcare companies appear to be attractive bets for those willing to stay the course for the next five years (and even beyond that).

Let's consider these excellent candidates: CRISPR Therapeutics ( CRSP 1.24% ) and Vertex Pharmaceuticals ( VRTX +0.96% ) , two innovative drugmakers. Here's why they are both buys heading into 2026.

1. CRISPR Therapeutics

CRISPR Therapeutics, a gene-editing specialist , should have several catalysts next year that could jolt its stock price. First, the biotech could make commercial and clinical progress with Casgevy, a medicine for sickle cell disease and beta-thalassemia d

See Full Page